1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Diurnal Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Diurnal Ltd (Diurnal) is a pharmaceutical company. The company develops drugs in the fields of adrenal insufficiency, hypogonadism, rheumatoid arthritis and hypothyroidism. Its products include Chronocort, Rheumacort, Infacort, Tri4Combi and native oral testosterone. Diurnal’s Chronocort is a physiological cortisol replacement product for the treatment of adrenal insufficiency and congenital adrenal hyperplasia. The company’s Rheumacort is an anti-inflammatory treatment that alleviates symptoms of rheumatoid arthritis. It develops physiological native oral testosterone replacement treatment for patients with hypogonadism. The company markets its products under the brands, namely, Infacort, Chronocort, Rheumacort and Tri4Combi. It has partnership with fusion, cyllid cymru finance wales, VIKING FUND and Sarum partners. Diurnal is headquartered in Cardiff, the UK.

Diurnal Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Diurnal Ltd - Pharmaceuticals and Healthcare - Deals and Alliances Profile
Table of Contents


Table of Contents 2

List of Tables
3

List of Figures
4
Diurnal Ltd, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
Diurnal Ltd, Pharmaceuticals and Healthcare Deals By Type, 2009 to YTD 2015 6
Diurnal Ltd, Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 7
Diurnal Ltd, Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8
Diurnal Ltd, Pharmaceuticals and Healthcare, Deals Summary, 2009 to YTD 2015 9
Diurnal Ltd, Pharmaceuticals and Healthcare, Deal Details 10
Venture Financing 10
Diurnal to Raise USD10 Million in Venture Financing 10
Diurnal Raises US$1.8 Million In Venture Financing 11
Diurnal Raises US$0.52 Million In Venture Financing 12
Diurnal Secures US$1.23 Million In Venture Financing 13
Diurnal Secures US$0.98 Million In Venture Financing 14
Diurnal Raises US$0.37 Million In Venture Financing 15
Diurnal Ltd - Key Competitors 16
Key Employees 17
Locations And Subsidiaries 18
Head Office 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19


List of Tables

Diurnal Ltd, Pharmaceuticals and Healthcare, Key Facts 1
Diurnal Ltd, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
Diurnal Ltd, Pharmaceuticals and Healthcare Deals By Type, 2009 to YTD 2015 6
Diurnal Ltd, Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 7
Diurnal Ltd, Deals By Therapy Area, 2009 to YTD 2015 8
Diurnal Ltd, Pharmaceuticals and Healthcare, Deals Summary, 2009 to YTD 2015 9
Diurnal to Raise USD10 Million in Venture Financing 10
Diurnal Raises US$1.8 Million In Venture Financing 11
Diurnal Raises US$0.52 Million In Venture Financing 12
Diurnal Secures US$1.23 Million In Venture Financing 13
Diurnal Secures US$0.98 Million In Venture Financing 14
Diurnal Raises US$0.37 Million In Venture Financing 15
Diurnal Ltd, Key Competitors 16
Diurnal Ltd, Key Employees 17


List of Figures

Diurnal Ltd, Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 1
Diurnal Ltd, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 1
Diurnal Ltd, Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 1
Diurnal Ltd, Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
Diurnal Ltd, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
Diurnal Ltd, Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 6
Diurnal Ltd, Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 7
Diurnal Ltd, Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8

Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016 ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.